Form 4: Guardant Health CLO Boosts Stake via RSU Vesting
Insider Transaction Report
Guardant Health's Chief Legal Officer, John G. Saia, increased his beneficial ownership of common stock through the vesting of restricted stock units and performance-based restricted stock units on January 1, 2026.
Summary
- John G. Saia, Chief Legal Officer of Guardant Health, Inc. (GH), reported multiple transactions on January 1, 2026.
- Saia acquired a total of 19,046 shares of common stock through the vesting of various Restricted Stock Unit (RSU) and Performance-Based Restricted Stock Unit (PSU) awards.
- These acquisitions included 974 RSUs, 7,792 performance-based RSUs, 1,667 RSUs, 5,688 performance-based RSUs, and 2,925 RSUs, all at an exercise price of $0.
- Concurrently, 9,989 shares of common stock were disposed of by the company at a price of $102.14 per share to cover tax withholding obligations related to the vesting of an RSU installment.
- Following these transactions, Saia's direct beneficial ownership of Guardant Health common stock increased to 52,714 shares.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive due to the vesting of a significant number of equity awards, indicating performance achievement and continued executive alignment, despite the routine disposition for tax purposes.
Positives
- The vesting of 19,046 shares of restricted stock units and performance-based restricted stock units indicates the achievement of time-based vesting schedules and performance metrics for the awards.
- The increase in beneficial ownership by a key executive like the Chief Legal Officer can be seen as a positive signal of alignment with shareholder interests and confidence in the company's future.
Negatives
- A disposition of 9,989 shares occurred to cover tax withholding obligations, which, while a standard practice, represents a reduction in the executive's direct shareholding.
Future Outlook
The filing indicates future vesting events for certain performance-based restricted stock units, with 34% of an award granted on February 26, 2024, scheduled to vest on January 1, 2027.
Industry Context
This Form 4 filing reflects routine executive compensation practices within the biotechnology and healthcare diagnostics industry, where equity awards like RSUs and PSUs are common tools for aligning executive incentives with long-term company performance and shareholder value.
Stakeholder Impact
- Shareholders: The increase in executive beneficial ownership may signal management's confidence, potentially aligning executive interests with shareholder value creation.
- Employees (specifically the reporting person): The vesting of equity awards represents a realization of compensation tied to company performance and tenure.
Next Steps
- The remaining 34% of the performance-based restricted stock unit award granted on February 26, 2024, is scheduled to vest on January 1, 2027.
Key Dates
| Date | Description |
|---|---|
| 2022-11-07 | Grant date for a Restricted Stock Unit award that vests over a four-year period. |
| 2023-06-07 | Grant date for a Performance-Based Restricted Stock Unit award with a 2-year vest period. |
| 2023-10-01 | Vesting date for 25% of the RSU award granted on November 7, 2022. |
| 2023-12-13 | Grant date for a Restricted Stock Unit award that vests over a three-year period. |
| 2024-02-26 | Grant date for a Performance-Based Restricted Stock Unit award. |
| 2024-10-01 | Vesting date for 33% of the RSU award granted on December 13, 2023. |
| 2024-11-08 | Grant date for a Restricted Stock Unit award that vests over a three-year period. |
| 2025-03-01 | Vesting date for 33% of the Performance-Based RSU award granted on February 26, 2024. |
| 2025-10-01 | Vesting date for 33% of the RSU award granted on November 8, 2024. |
| 2026-01-01 | Date of earliest transaction, including vesting of multiple RSU and PSU awards and disposition for tax withholding. |
| 2026-01-05 | Signature date of the reporting person for the Form 4 filing. |
| 2027-01-01 | Future vesting date for the remaining 34% of the Performance-Based RSU award granted on February 26, 2024. |
Keywords
Guardant Health, GH, SEC Form 4, Insider Transaction, Restricted Stock Units, Performance-Based Restricted Stock Units, RSU Vesting, Executive Compensation, Beneficial Ownership, Chief Legal Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.